Effect of STN-DBS frequency on cortical excitability and motor performance in Parkinson's disease

ConclusionsStimulation of STN at 80 Hz and 130 Hz may have different effects on proximal and distal muscle control. One hundred and thirty Hertz may have a small advantage for distal hand muscles, whereas 80 Hz is more effective in improving proximal muscle function.
Source: Neurophysiologie Clinique - Category: Neuroscience Source Type: research

Related Links:

Abbott Laboratories is adding some extra firepower to its neuromodulation offerings. The company said last week that its Infinity Deep Brain Stimulation [DBS] device received a nod from FDA to treat Parkinson’s disease symptoms. The newly approved indication specifically calls for the Infinity DBS to target an area of the brain called the globus pallidus (GPi). Abbott said the GPi plays an integral role in the motor function and can be targeted with DBS to improve Parkinson’s disease symptoms not adequately controlled by medication. Abbott said with this approval, the Infinity DBS is now...
Source: MDDI - Category: Medical Devices Authors: Tags: Regulatory and Compliance Business Source Type: news
Abbott has announced that the FDA has given the company the first ever approval for a device to treat Parkinson’s by delivering deep brain stimulation (DBS) to the internal globus pallidus (GPi), an area associated with motor function. The Infi...
Source: Medgadget - Category: Medical Devices Authors: Tags: Neurology Neurosurgery Source Type: blogs
Abbott's Infinity™ DBS is the first FDA approved directional Deep Brain Stimulation (DBS) system to allow targeting of a specific area of the brain that is critical to motor functions Approximately 60,000 Americans are diagnosed with Parkinson's disease... Devices, Neurology, FDA Abbott, Infinity, Deep Brain Stimulation, Parkinson's Disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Conclusions: STN-DBS is a safe procedure and can be performed in all patients of PD who develop disabling motor fluctuations to improve their QoL irrespective early or advanced disease.
Source: Annals of Indian Academy of Neurology - Category: Neurology Authors: Source Type: research
AbstractThe brainstem-based pedunculopontine nucleus (PPN) traditionally associates with motor function, but undergoes extensive degeneration during Parkinson ’s disease (PD), which correlates with axial motor deficits. PPN-deep brain stimulation (DBS) can alleviate certain symptoms, but its mechanism(s) of action remains unknown. We previously characterized rats hemi-intranigrally injected with the proteasomal inhibitor lactacystin, as an accurate prec linical model of PD. Here we used a combination of chemogenetics with positron emission tomography imaging forin vivo interrogation of discrete neural networks in thi...
Source: Neurotherapeutics - Category: Neurology Source Type: research
Deep brain stimulation (DBS) is a widely accepted therapy for Parkinson's disease. While outcome predictors such as levodopa-response are well established, there remains a need for objective and unbiased predictors in clinical practice. We performed an exploratory study to examine whether cortical thickness, derived from preoperative MRI, correlates with postoperative outcome.
Source: Parkinsonism and Related Disorders - Category: Neurology Authors: Source Type: research
Abstract Deep brain stimulation (DBS) of the pedunculopontine nucleus (PPN) has been proposed as a treatment strategy for gait disorder in patients with Parkinson's disease (PD). We thus performed a systematic review and meta-analysis of randomized and nonrandomized controlled trials to assess the effect of this treatment on gait disorder in patients with PD. We systematically searched PubMed, Cochrane, Web of Knowledge, Wan Fang and WIP for randomized and nonrandomized controlled trials (published before July 29, 2014; no language restrictions) comparing PPN-DBS with other treatments. We assessed pooled data usin...
Source: Neurochemical Research - Category: Neuroscience Authors: Tags: Neurochem Res Source Type: research
Medtronic obtained the European CE Mark for its Percept PC neurostimulator that uses smart feedback technology to deliver deep brain stimulation to treat Parkinson’s and other neurologic diseases. The so-called BrainSense technology powe...
Source: Medgadget - Category: Medical Devices Authors: Tags: Neurology Neurosurgery Source Type: blogs
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by hypokinetic motor features; however, patients also display non-motor symptoms like sleep disorders. The standard treatment for PD is dopamine replacement with L-DOPA; however, symptoms including gait deficits and sleep disorders are unresponsive to L-DOPA. Notably, these symptoms have been linked to aberrant activity in the pedunculopontine nucleus (PPN). Of late, clinical trials involving PPN deep brain stimulation (DBS) have been employed to alleviate gait deficits. Although preclinical evidence implicating PPN cholinergic neurons in gait dys...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Abstract Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an effective therapeutic strategy for motor symptoms of Parkinson's disease (PD) when L-DOPA therapy induces disabling side effects. Classical inflammatory activation of glial cells is well established in PD, contributing to the progressive neurodegenerative state; however, the role of DBS in regulating the inflammatory response remains largely unknown. To understand the involvement of astrocytes in the mechanisms of action of DBS, we evaluated the effect of STN-DBS in regulating motor symptoms, astrocyte reactivity, and cytokine expression ...
Source: Cellular and Molecular Neurobiology - Category: Cytology Authors: Tags: Cell Mol Neurobiol Source Type: research
More News: Brain | Deep Brain Stimulation | Neurology | Neuroscience | Neurosurgery | Parkinson's Disease | Study